Advertisement
U.S. markets closed

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.01+0.77 (+3.31%)
At close: 04:00PM EST
23.41 -0.60 (-2.50%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close23.24
Open23.52
Bid23.40 x 1000
Ask24.50 x 900
Day's Range23.35 - 24.53
52 Week Range17.71 - 33.99
Volume2,500,271
Avg. Volume1,956,754
Market Cap3.956B
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateMay 06, 2024 - May 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.65
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACAD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ACADIA Pharmaceuticals Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more